- Mixed Q3, but with signs of improvements - We revise EBITDA down by 1.
- Order intake +2% y-o-y on return of one key customer - '25-'26e EBIT up 11-13% on higher gross mar...
- Technical production disruptions in the hot cell - Scandpower showing positive signs - We lower '2...
- Q3 earnings miss reduces '24e EBIT, but order beat raises '25e - Market activity remains high and ...
EMS market has been weak but Incap was able to improve net sales in y/y and also in q/q basis.
Det svenska bioteknikbolaget Aptahem AB (publ) (”Aptahem” eller ”Bolaget”) utvecklar RNA-baserade lä...
Redeye increases its fair value range following a closer look at the report.
Relative profitability remained good but net sales declined by 19% in Q3 y/y driven by weak customer...
Redeye sees a weak Q3 negatively impacted by a soft market and postponed projects.
Redeye believes Sdiptech's Q3 report was weaker than expected, with continued positive organic sales...
Redeye sees a stable Q3 from Formpipe, with sales and adjusted EBIT roughly matching our expectation...
Redeye comments on Doro´s third quarter of the year.
Svedbergs Group posted a soft set of Q3 2024 numbers, with sales coming in 4% below our estimates (n...
Redeye makes negligible changes to its forecasts and valuation following Stille's Q3 report.
Redeye comments on ENEA's Q4 2024 report, which, on a like-for-like basis, aligned with estimates.
